Open AccessInterferon gamma in the treatment of patients with moderate COVID-19
Author(s) -
A. L. Myasnikov,
Svetlana Berns,
П. А. Талызин,
Ф. И. Ершов
Publication year - 2021
Publication title -
voprosy virusologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.151
H-Index - 15
eISSN - 2411-2097
pISSN - 0507-4088
DOI - 10.36233/0507-4088-24
Subject(s) - medicine , pneumonia , viral pneumonia , interferon , intensive care unit , immune system , vital signs , coronavirus , covid-19 , community acquired pneumonia , interferon gamma , immunology , disease , surgery , infectious disease (medical specialty)
Interferons are produced in response to the presence of pathogens in cells and are responsible for the proper formation of immune reaction. Preliminary data obtained in studies of properties of recombinant interferon gamma (IFN-γ) that involved patients with community-acquired pneumonia (including bacterial), acute respiratory viral infection (ARVI), influenza and new coronavirus infection have shown promising results.The purpose of the study was to assess the effect of subcutaneous administration of IFN-γ in patients with viral pneumonia on the changes of vital signs and the duration of hospital stay.